Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials

被引：8
|
作者：
Eskander, Ramez N. [1 ]
Powell, Matthew A. [2 ]
机构：
[1] Univ Calif San Diego, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, Moores Canc Ctr, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA
[2] Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷
关键词：
antiangiogenic therapy; chemotherapy; combination therapy; endometrial cancer; immune checkpoint inhibition; immunotherapy; tumor mutational burden; CARBOPLATIN; PACLITAXEL;
D O I：
10.1177/17588359211001199
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an effective standard-of-care regimen, alternate strategies have shown promise, particularly in biomarker select populations. In an effort to improve oncologic outcomes, investigators are exploring novel immunotherapy combinations. In this review, we discuss the clinical rationale and design of current phase III immuno-oncology clinical trials in patients with advanced stage or recurrent endometrial cancer.
引用
收藏
页数：9
相关论文
共 50 条
  • [31] Current phase III breast cancer clinical trials
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (07): : 696 - +
  • [32] PASSIVE, ADOPTIVE AND ACTIVE IMMUNOTHERAPY - A REVIEW OF CLINICAL-TRIALS IN CANCER
    MATHE, G
    GOUVEIA, J
    ERIGUCHI, M
    REIZENSTEIN, P
    INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, 1985, 1 (03): : 139 - 150
  • [33] Are the Real World Patients with Advanced Non-Small Cell Lung Cancer Represented in Phase III Immunotherapy Trials?
    Ce Coelho, J.
    Rebelato, T.
    Gelatti, A.
    D'Avila, R.
    Geib, G.
    Rubini Liedke, P.
    Peres Pereira, R.
    Werutsky, G.
    Jobim De Azevedo, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1918 - S1918
  • [34] Sequential immunotherapy and association with clinical outcomes in advanced-stage cancer patients
    Bilen, Mehmet
    Martini, Dylan
    Liu, Yuan
    Lewis, Colleen
    Collins, Hannah
    Shabto, Julie
    Akce, Mehmet
    Kissick, Haydn
    Carthon, Bradley
    Shaib, Walid
    Alese, Olatunji
    Pillai, Rathi
    Steuer, Conor
    Wu, Christina
    Lawson, David
    Kudchadkar, Ragini
    El-Rayes, Bassel
    Master, Viraj
    Ramalingam, Suresh
    Owonikoko, Taofeek
    Harvey, R. Donald
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [35] Current cooperative group phase III clinical trials in early-stage breast cancer
    不详
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 176 - +
  • [36] Treatment strategy after the discontinuation of immunotherapy for head and neck cancer: a review
    Wakasugi, Tetsuro
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2023, 9
  • [37] Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer: a meta-analysis of randomized controlled trials
    Bogani, Giorgio
    Monk, Bradley J.
    Barretina-Ginesta, Maria-Pilar
    Raspagliesi, Francesco
    Colombo, Nicoletta
    Slomovitz, Brian
    Mirza, Mansoor Raza
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A193 - A193
  • [38] How to integrate immunotherapy into treatment strategy for locally advanced head and neck cancer
    Cohen, Ezra E. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1368 - S1368
  • [39] Novel Therapeutics in Advanced Breast Cancer: A Review of Current Phase I Clinical Trials
    Vemuru, Shalini
    Kalinsky, Kevin
    Bhave, Manali
    CURRENT BREAST CANCER REPORTS, 2025, 17 (01)
  • [40] Navigating the future of pancreatic cancer treatment: Systematic review insights from immunotherapy clinical trials.
    Sarfraz, Zouina
    Anwar, Junaid
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 68 - 68
12345